Future Consumer reports consolidated net loss of Rs 15.80 crore in the June 2024 quarter

Future Consumer reports consolidated net loss of Rs 15.80 crore in the June 2024 quarter


Sales rise 19.85% to Rs 106.39 crore

Net Loss of Future Consumer reported to Rs 15.80 crore in the quarter ended June 2024 as against net loss of Rs 24.39 crore during the previous quarter ended June 2023. Sales rose 19.85% to Rs 106.39 crore in the quarter ended June 2024 as against Rs 88.77 crore during the previous quarter ended June 2023.

ParticularsQuarter EndedJun. 2024Jun. 2023% Var.Sales106.3988.77 20 OPM %-0.70-8.72 PBDT-11.91-17.18 31 PBT-15.77-22.57 30 NP-15.80-24.39 35

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Aug 14 2024 | 6:14 PM IST



Source link

Future Consumer reports consolidated net loss of Rs 15.80 crore in the June 2024 quarter

Worldwide Aluminium reports standalone net loss of Rs 0.02 crore in the June 2024 quarter


Sales reported at Rs 4.33 crore

Net Loss of Worldwide Aluminium reported to Rs 0.02 crore in the quarter ended June 2024 as against net loss of Rs 0.21 crore during the previous quarter ended June 2023. Sales reported to Rs 4.33 crore in the quarter ended June 2024. There were no Sales reported during the previous quarter ended June 2023.

ParticularsQuarter EndedJun. 2024Jun. 2023% Var.Sales4.330 0 OPM %-0.460 PBDT-0.02-0.21 90 PBT-0.02-0.21 90 NP-0.02-0.21 90

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Aug 14 2024 | 5:58 PM IST



Source link

Future Consumer reports consolidated net loss of Rs 15.80 crore in the June 2024 quarter

Capacit'e Infraprojects consolidated net profit rises 180.07% in the June 2024 quarter


Sales rise 32.36% to Rs 569.75 crore

Net profit of Capacit’e Infraprojects rose 180.07% to Rs 53.41 crore in the quarter ended June 2024 as against Rs 19.07 crore during the previous quarter ended June 2023. Sales rose 32.36% to Rs 569.75 crore in the quarter ended June 2024 as against Rs 430.45 crore during the previous quarter ended June 2023.

ParticularsQuarter EndedJun. 2024Jun. 2023% Var.Sales569.75430.45 32 OPM %18.9516.38 PBDT94.9950.45 88 PBT71.7525.96 176 NP53.4119.07 180

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Aug 14 2024 | 4:54 PM IST



Source link

Future Consumer reports consolidated net loss of Rs 15.80 crore in the June 2024 quarter

Mazagon Dock spurts as Q1 PAT soars 121% YoY


Mazagon Dock Shipbuilders rallied 3.15% to Rs 4,985 after the company’s consolidated net profit zoomed 121.45% to Rs 696.10 crore in Q1 FY25 from Rs 314.34 crore reported in Q1 FY24.

Revenue from operations grew by 8.48% to Rs 2,357.02 crore in Q1 FY25 as compared with Rs 2,172.76 crore recorded in the corresponding quarter previous year.

Profit before tax stood at Rs 888.79 crore in Q1 FY25, registering a growth of 131.87% from Rs 383.32 crore posted in Q1 FY24.

EBITDA soared 126% year on year to Rs 913 crore in the quarter ended 30 June 2024. Operating margin jumped to 26% in Q1 FY25 as compared with 7% registered in Q1 FY24.

Total expenses were at Rs 1739.23 crore in Q1 FY25, down 14% YoY. Cost of materials consumed was at Rs 1106.19 crore (down 22.85% YoY) while power and fuel stood at Rs 4.74 crore (up 10.75% YoY) during the period under review.

The shipbuilding companys total order book stood at Rs 36,839 crore as on 30 June 2024.

Mazagon Dock Shipbuilders is principally engaged in building and repairing of ships, submarines, various types of vessels and related engineering products for its customers.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Aug 14 2024 | 4:01 PM IST



Source link

10 things global fund managers are saying about equity markets; check here

10 things global fund managers are saying about equity markets; check here



It has been a rollercoaster ride for the global equity markets in the last few weeks, as they have braved a number of headwinds – from geopolitical tensions, a possible recession scare in the United States (US) to impact of the yen carry trade. 


So, is the worst over for the global markets? How will Japanese stock markets play out in the next few months? Is the US really headed into a recession? And, where does India stand in the preference list of global fund managers in this backdrop?

 


A total of 220 panelists with $590 billion worth of assets under management (AUM)) participated in a survey conducted by BofA Securities between August 2 and August 8 and shared their views on how they see global equities play out over the next few months.


Here are top 10 findings.


India stock market among most preferred: India remained the second most preferred investment destination with 39 per cent of fund managers being overweight on Indian equities. Japan topped this preference list with 41 per cent of the fund managers surveyed being overweight on the region.

“Tech-heavy Taiwan and Korea saw a drop in allocation, with the former displaced from a top-3 spot for the first time in nine months. Australia, China and Thailand remain unloved,” BofA Securities said.


BofA FMS survey August 2024


Betting big on consumption in India: In India, consumption (32 per cent preference) toppled infrastructure (15 per cent) as the favorite theme, BofA said, following a people-friendly budget.


Economic outlook: The Asia Pacific ex-Japan economic outlook, fund managers said, was relatively more stable, with 22 per cent of the fund managers surveyed expecting the regional economy to strengthen in the next 12 months versus 24 per cent in July.


Corporate profits: Corporate profit expectations in the Asian region took a beating, BofA’s findings suggest, with only 17 per cent of the respondents surveyed in August expecting a rise in profits in the next few months as compared to 57 per cent in July.

“Asia Pacific ex-Japan valuations, on the other hand, continue to be assessed as fair as they have throughout this year,” the BofA Securities note said.

Country preference


Country preference


Currency moves: Global investors (56 per cent investors in August versus 30 per cent in July), the BofA survey said, are now more focused on currency moves, which, besides other factors they feel, will dictate the market direction going ahead in Japan. Wage negotiations/BoJ policy normalisation, corporate governance reforms and JPX initiatives are some of the other factors that they believe will impact Japanese equities.


Worst over for Japan? Equities in Japan are expected to rise in the next 12 months, with 80 per cent of the fund managers surveyed by BofA Securities believing so, though only 46 per cent expect the Nikkei 225 index to hit a new high.


“Japan retains its spot as the favorite market in the region, as cited by 41 per cent of the participants, with a (curtailed) bias towards banks and semiconductors sectors,” BofA said.


China ‘s economy weakening?: BofA’s contrarian sentiment indicator for China equities hit the panic threshold in August, BofA said. 


“The FMS echoes the apathy, with net 10 per cent expecting the economy to weaken over the next 12 months – the lowest breadth since the start of the survey in 2022 – as the propensity to save among China households is all but cemented,” BofA said.


China stock market: Structural bearishness on the China equity markets stayed intact in August with 32 per cent of respondents remaining in a ‘wait-and-watch’ mode before increasing their exposure to the region. An equal number (32 per cent) of fund managers have already started scouting for other regions/stock markets to deploy funds versus 22 per cent in July.


Semiconductor cycle: After an extended period of dominance, BofA said, investor’s faith in the semiconductor cycle has been shaken, as the FMS cut its outlook to a 19-month low of around 30 per cent.


Sector preference: Investors, BofA said, continued to prefer technology in August, although there was a claw-back in allocation alongside a souring of sentiment towards other cyclical sectors such as energy and materials in favor of defensives like staples, healthcare and utilities on emerging US recession risks.

First Published: Aug 14 2024 | 2:42 PM IST



Source link

Marksans Pharma zooms to record high; stock up on strong Q1 results

Marksans Pharma zooms to record high; stock up on strong Q1 results


Shares of Marksans Pharma hit a record high of Rs 217, as they surged 16 per cent on the BSE in Wednesday’s intra-day trade amid heavy volumes after the company reported strong earnings for the June 2024 quarter (Q1FY25).

At 01:49 pm; the stock was trading 15 per cent higher at Rs 216.35, as compared to 0.24 per cent rise in the BSE Sensex. The average trading volumes at the counter jumped over three-fold. A combined 16 million shares changed hands on the NSE and BSE.


The pharmaceutical company posted 18 per cent year-on-year (YoY) increase in revenue at Rs 590.60 crore and 26 per cent YoY increase in earnings before interest, tax, depreciation and amortization (EBITDA) at Rs 128.4 crore. EBITDA margin improved to 21.7 per cent from 20.4 per cent in Q1FY24. Profit after tax jumped 26.5 per cent YoY at Rs 89.1 crore.


The US & North America Formulation business reported growth of 29.8 per cent YoY to Rs 250.90 crore in Q1FY25, on account of incremental revenue from new product launches, and increase in the share of existing customers. The company said 32 products are in the pipeline, of which 20 are oral solids and 12 are ointments and creams. Within oral solids, 4 are Softgels.


The management said the growth during the quarter was supported by increase in share from existing customers and new launches. The company experienced favorable raw material prices, however, surge in freight costs continue.


The shipments from the new facility have commenced to the company’s key markets, and with that the management remains optimistic for a stronger performance in the coming quarters, and journey towards achieving the next revenue goal of Rs 3,000 crore over the next two years.


Marksans Pharma is engaged in research, manufacturing & marketing of generic pharmaceutical formulation in the global markets. The company’s manufacturing facilities are approved by several leading regulatory agencies including the USFDA, UKMHRA and Australian TGA. The company’s robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

First Published: Aug 14 2024 | 2:10 PM IST



Source link

YouTube
Instagram
WhatsApp